Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab

Kobayashi, Tetsuo; Yokoyama, Tomoko; Ito, Satoshi; Kobayashi, Daisuke; Yamagata, Akira; Okada, Mihoko; Oofusa, Ken; Narita, Ichiei; Murasawa, Akira; Nakazono, Kiyoshi; Yoshie, Hiromasa

doi:10.1902/jop.2014.140194

Cited by 67 publications

(75 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complement factor H, serum amyloid A, complement component 4, phospholipase D and α-1-acid glycoprotein were assessed and these serum proteins decreased after ADA treatment [17].…”

Section: Serum Amyloid-amentioning

confidence: 99%

Acute Phase Proteins and Their Role in Periodontitis: A Review

Polepalle

Marmamula

Boggarapu

et al. 2015

JCDR

View full text Add to dashboard Cite

“…Complement factor H, serum amyloid A, complement component 4, phospholipase D and α-1-acid glycoprotein were assessed and these serum proteins decreased after ADA treatment [17].…”

Section: Serum Amyloid-amentioning

confidence: 99%

Acute Phase Proteins and Their Role in Periodontitis: A Review

Polepalle

Marmamula

Boggarapu

et al. 2015

JCDR

View full text Add to dashboard Cite

“…SSZ contains multiple anti-inflammatory components and is cleaved in the colon into acetylsalicylic acid and sulfapyridin and its antirheumatic mechanism is thought to involve inhibition of proinflammatory transcription factors [17]. The biological DMARDs include TNF- α inhibitors, anti-B cell therapy, T-cell costimulation blockers, IL-6 inhibitors, IL-1 inhibitors, and protein kinase inhibitors [20, 21]. …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Several studies have indicated that biological DMARDs, sometimes classified as anticytokines, improve various measures of periodontal health [21–24]. Adalimumab, a TNF- α inhibitors, was recently shown to significantly decrease probing depth (PD) and bleeding on probing (BOP) in patients with RA [21]. Other common drugs for RA, such as NSAIDS and steroids, have been also suggested to affect the periodontal inflammatory status [22, 23], as determined by biomarkers of inflammation in the gingival crevicular fluid [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis

Jung

Han

Hwang

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) and periodontitis are common chronic inflammatory diseases and periodontitis is known to be more common and more severe in patients with RA. Based on a paucity of studies about the relationship between common conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and periodontitis, this prospective study aimed to evaluate the adjunctive effect of csDMARDs on response to nonsurgical periodontal treatment in patients with RA. Thirty-two patients with RA (RA group) and 32 systemically healthy patients (control group) with periodontitis were included in this study. The RA group patients were treated with csDMARDs, such as methotrexate, hydroxychloroquine, and sulfasalazine. Conventional nonsurgical periodontal treatment with scaling and root planing was performed in both groups. The extent and severity of periodontitis were evaluated by plaque index (PI), gingival index (GI), probing depth (PD), clinical attachment level (CAL), and bleeding on probing (BOP) at baseline and 4 weeks after periodontal treatment. There was no statistically significant difference of periodontal parameters between the RA and control groups at baseline. Four weeks after scaling and root planing, PD reduction, and CAL gain were higher in the RA group treated with csDMARDs compared to the control group, and the difference was statistically significant (P = 0.006 and 0.003, respectively). A post hoc analysis of the RA group showed no statistically significant difference on the response to nonsurgical periodontal treatment in multiple csDMARDs therapy and addition of NSAIDs and/or steroids to csDMARDs. In patients with RA, csDMARDs showed beneficial effect on periodontal clinical parameters following the nonsurgical periodontal treatment.

show abstract

“…In contrast, the same study failed to show that treatment with methotrexate had any effects on the periodontal status . A recent short‐term study assessing the effects of humanized anti‐tumor necrosis factor‐alpha monoclonal antibody therapy (Adalimumab ® ) on the periodontal condition of patients with rheumatoid arthritis, by comparing serum protein profiles before and after such therapy, identified significant decreases in bleeding on probing and probing depth and in the serum levels of C‐reactive protein, tumor necrosis factor‐alpha and interleukin‐6 . In another cross‐sectional case–control study on patients with rheumatoid arthritis in which different combinations and dosages of ibuprofen, diclofenac, prednisone and paracetamol were studied, the authors observed that although no differences in clinical periodontal conditions were found between individuals with or without a diagnosis of rheumatoid arthritis, the gingival crevicular fluid levels of interleukin‐1beta and elastase were significantly lower in the rheumatoid arthritis group.…”

Section: The Impact Of Medical Therapies On Periodontal Statusmentioning

confidence: 97%

Treatment of periodontal disease in older adults

Renvert¹,

Persson²

2016

Periodontology 2000

View full text Add to dashboard Cite

Within the next 40 years the number of older adults worldwide will more than double. This will impact periodontal treatment needs and presents a challenge to health-care providers and governments worldwide, as severe periodontitis has been reported to be the sixth most prevalent medical condition in the world. Older adults (≥ 80 years of age) who receive regular dental care retain more teeth than those who do not receive such care, but routine general dental care for these individuals is not sufficient to prevent the progression of periodontitis with the same degree of success as in younger individuals. There is a paucity of data on the efficacy of different periodontal therapies for older individuals. However, considering the higher prevalence of chronic medical conditions seen in older adults, it cannot be assumed that periodontal therapy will yield the same degree of success seen in younger individuals. Furthermore, medications can influence the status of the periodontium and the delivery of periodontal care. As an example, anticoagulant drugs are common among older patients and may be a contraindication to certain treatments. Newer anticoagulants will, however, facilitate surgical intervention in older patients. Furthermore, prescription medications taken for chronic conditions, such as osteoporosis and cardiovascular diseases, can affect the periodontium in a variety of ways. In summary, consideration of socio-economic factors, general health status and multiple-drug therapies will, in the future, be an important part of the management of periodontitis in older adults.

show abstract

Periodontal and Serum Protein Profiles in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitor Adalimumab

Abstract: These results suggest a beneficial effect of ADA therapy on the periodontal condition of patients with RA, which might be related to differences in serum protein profiles before and after ADA therapy.

Cited by 67 publications

References 51 publications

Acute Phase Proteins and Their Role in Periodontitis: A Review

Acute Phase Proteins and Their Role in Periodontitis: A Review

Effects of Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Response to Periodontal Treatment in Patients with Rheumatoid Arthritis

Treatment of periodontal disease in older adults

Contact Info

Product

Resources

About